drugset / Trial / NCT01505881
Follow on Study From RE-ALIGN
Non-randomizedParallel-groupOpen-labelPrevention
Summary
To collect additional data relating to safety and indicators of efficacy for patients who have participated in the 1160.113 study.
Timeline
- Start
- 2011-12
- Primary completion
- 2013-06
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabigatran etexilate | Unknown | 150 mg | Oral |
| Subject | Dabigatran etexilate | Unknown | 220 mg | Oral |
| Subject | Dabigatran etexilate | Unknown | 300 mg | Oral |
| Comparator | Warfarin | Small molecule | 1 mg | — |
| Comparator | Warfarin | Small molecule | 3 mg | — |
| Comparator | Warfarin | Small molecule | 5 mg | — |